title: Reciprocal Regulation of 11β-HSDs May Predict Steroid Sensitivity in Childhood Nephrotic Syndrome.
abstract: Childhood nephrotic syndrome, in which steroid-dependence occurs concurrently with steroid-resistance, requires aggressive therapy to prevent relapse. Predictive biomarkers that can be used to stratify treatment are urgently needed. Here we report that reciprocal regulation of the glucocorticoid metabolizing enzymes, 11β-hydroxysteroid dehydrogenase types 1 and 2, is associated with steroid-responsiveness and disease remission in childhood nephrotic syndrome, potentially providing a marker to identify patients in which aggressive therapy is required.
authors: Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan; Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, Scotland; shuji-sai@keijinkai.or.jp.
authors: Shuji
authors: S
authors: Sai
authors: Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Pediatrics, Seirei Hamamatsu General Hospital, Hamamatsu, Japan; and.
authors: Masaki
authors: M
authors: Yamamoto
authors: Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan;
authors: Rie
authors: R
authors: Yamaguchi
authors: Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, Scotland;
authors: Karen E
authors: KE
authors: Chapman
authors: Department of Pediatrics, Iwata City Hospital; Iwata, Japan.
authors: Teruaki
authors: T
authors: Hongo
mesh_terms: D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1 / Q000097:blood*; D043209:11-beta-Hydroxysteroid Dehydrogenase Type 2 / Q000097:blood*; D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003907:Dexamethasone / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004351:Drug Resistance; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy; D060046:Maintenance Chemotherapy; D008297:Male; D009404:Nephrotic Syndrome / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology; D011239:Prednisolone / Q000627:therapeutic use*; D011965:Receptors, Glucocorticoid / Q000097:blood; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D015415:Biomarkers; C497713:NR3C1 protein, human; D011965:Receptors, Glucocorticoid; D003907:Dexamethasone; D011239:Prednisolone; D043205:11-beta-Hydroxysteroid Dehydrogenase Type 1; D043209:11-beta-Hydroxysteroid Dehydrogenase Type 2; C468386:HSD11B1 protein, human; C468387:HSD11B2 protein, human